Veritex Holdings, Inc. (VBTX) Reaches $30.78 52-Week High; COSMO PHARMACEUTICALS NV ORDINARY SHARES (CMOPF) SI Decreased By 3.17%

May 18, 2018 - By Adrian Mccoy

Veritex Holdings, Inc. (NASDAQ:VBTX) Logo

COSMO PHARMACEUTICALS NV ORDINARY SHARES (OTCMKTS:CMOPF) had a decrease of 3.17% in short interest. CMOPF’s SI was 210,700 shares in May as released by FINRA. Its down 3.17% from 217,600 shares previously. The SI to COSMO PHARMACEUTICALS NV ORDINARY SHARES’s float is 3.57%. It closed at $143 lastly. It is down 0.00% since May 18, 2017 and is . It has underperformed by 11.55% the S&P500.

The stock of Veritex Holdings, Inc. (NASDAQ:VBTX) hit a new 52-week high and has $32.93 target or 7.00% above today’s $30.78 share price. The 9 months bullish chart indicates low risk for the $743.30 million company. The 1-year high was reported on May, 18 by Barchart.com. If the $32.93 price target is reached, the company will be worth $52.03M more. The stock increased 0.42% or $0.13 during the last trading session, reaching $30.78. About 31,730 shares traded. Veritex Holdings, Inc. (NASDAQ:VBTX) has declined 2.33% since May 18, 2017 and is downtrending. It has underperformed by 13.88% the S&P500.

Among 7 analysts covering Veritex Holdings (NASDAQ:VBTX), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Veritex Holdings has $34 highest and $20 lowest target. $32.83’s average target is 6.66% above currents $30.78 stock price. Veritex Holdings had 10 analyst reports since October 28, 2015 according to SRatingsIntel. As per Wednesday, October 28, the company rating was maintained by Stephens. As per Thursday, July 20, the company rating was maintained by Stephens. As per Thursday, February 1, the company rating was upgraded by PiperJaffray. The firm has “Buy” rating given on Tuesday, April 24 by Piper Jaffray. The firm earned “Buy” rating on Tuesday, April 24 by Sandler O’Neill. The firm has “Hold” rating by Piper Jaffray given on Tuesday, October 24. Keefe Bruyette & Woods initiated Veritex Holdings, Inc. (NASDAQ:VBTX) rating on Tuesday, January 16. Keefe Bruyette & Woods has “Buy” rating and $33.0 target.

Veritex Holdings, Inc. operates as the holding firm for Veritex Community Bank that provides various commercial banking services and products to small and medium-sized businesses, and professionals. The company has market cap of $743.30 million. The company's deposit products include checking, demand, savings, money market, and time accounts, as well as commercial deposit and financial institution money market accounts. It has a 38.47 P/E ratio. The Company’s loan portfolio consists of commercial real estate and general commercial loans, residential real estate loans, and consumer loans.

Analysts await Veritex Holdings, Inc. (NASDAQ:VBTX) to report earnings on July, 18. They expect $0.44 earnings per share, up 91.30% or $0.21 from last year’s $0.23 per share. VBTX’s profit will be $10.63M for 17.49 P/E if the $0.44 EPS becomes a reality. After $0.42 actual earnings per share reported by Veritex Holdings, Inc. for the previous quarter, Wall Street now forecasts 4.76% EPS growth.

More news for Veritex Holdings, Inc. (NASDAQ:VBTX) were recently published by: Globenewswire.com, which released: “Veritex Holdings, Inc. Reports Record First Quarter Financial Results” on April 23, 2018. Seekingalpha.com‘s article titled: “Veritex Holdings’ (VBTX) CEO Malcolm Holland on Q1 2018 Results – Earnings Call Transcript” and published on April 24, 2018 is yet another important article.

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, engages in developing therapies for gastrointestinal disorders and endoscopic procedures worldwide. The company has market cap of $1.74 billion. The company??s proprietary clinical development pipeline primarily addresses treatments for the gastro-intestinal tract, inflammatory bowel diseases , colon infections, and colon diagnosis. It currently has negative earnings. It markets Lialda/Mezavant/Mesavancol, an oral tablet formulation for the treatment of IBD; UCERIS/Cortiment, a glucocorticosteroid indicated for the induction of remission in active, mild to moderate Ulcerative Colitis; and Zacol NMX, a nutraceutical product that uses an amended form of the MMX technology in order to deliver butyric acid and inulin directly to the colon.

Veritex Holdings, Inc. (NASDAQ:VBTX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>